Survey of current status of post-mastectomy radiotherapy for breast cancer in China
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF RADIATION ONCOLOGY
- Issue:
- 6
- DOI:
- 10.3760/j.issn:1004-4221.2005.06.002
- Key Word:
- 乳腺肿瘤/放射疗法;适应证;问卷调查
Abstract： 目的为了全面了解我国目前乳腺癌根治术或改良根治术后放疗(简称术后放疗) 的现状,特开展此项研究.方法对全国所有开展放疗的单位分别于2003年1～3月邮寄调查表 ,对乳腺癌术后放疗的适应证和放疗技术等进行两轮问卷调查. 结果乳腺癌术后放疗适应证中包含T1～T2期病变及位于内象限或中央区、T1～T2期淋巴结转移1～3个、T3期或淋巴结转移≥4个的单位比例分别为11.9%、63.8%、87.6%和97.1%,其中仅以T3期或淋巴结转移≥4个为术后放疗主要适应证的单位只占7.1%.在放疗靶区中,常规照射锁骨上下区的单位最多, 占96.2%,其余依次为内乳区85.2%、胸壁79.0%和腋窝74.8%.胸壁照射以60Co或高能 X线切线野照射最多见(45.2%),单纯电子线照射占28.3%,60Co或高能X线与电子线混合照射占 25.3%;34.3%的单位在照射中胸壁加垫填充物;胸壁的中位照射剂量是50 Gy(30～60 Gy ).腋窝照射以60Co或高能X线为主(86.6%),与电子线混合照射占12.7%;有65.6%的单位采用腋后野补量照射技术;腋窝中位照射剂量是50 Gy(40～64 Gy).锁骨上下区也以 60Co或高能X线照射为主(61.4%),与电子线混合照射占33.7%;锁骨上下区中位照射剂量是50 Gy(40～ 60 Gy ).内乳区单纯60Co或高能X线照射占49.7%,与电子线混合照射占33.0%,单纯电子线照射占15.6%;内乳区中位照射剂量也是50 Gy(40～60 Gy).结论目前我国对肿瘤≥5 cm 或淋巴结转移≥4个的乳腺癌进行术后放疗的看法比较一致,但对T1～T2期淋巴结转移1～3个的患者是否需要术后放疗的看法尚存分歧,有待进一步的前瞻性临床研究来证实.
- [1]殷蔚伯,田凤华.2001年全国放射治疗人员及设备调查报告[J].2002,(3).
- [2]惠周光,李晔雄,吴君心,等.乳腺癌术后腋窝淋巴结数对放射治疗的指导意义[J].2001,(3).
- [3]惠周光,余子豪.早期乳腺癌根治术或改良根治术后的放射治疗[J].2001,(1).
- [4]王淑莲,李晔雄,余子豪.早期乳腺癌患者根治术后的放射治疗[J].2002,(1).
- [5]Brouwers M,Huang J,Mackillop WJ,etc.Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review.[J].2003,21(3).
- [6]A, Goldhirsch,R D, Gelber,M, Castiglione.Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses.[J].1988,6.
- [7]M, Kaufmann,W, Jonat,U, Abel,etc.Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.[J].1993,11.
- [8]L B, Marks,M E, Hebert,G, Bentel,etc.To treat or not to treat the internal mammary nodes: a possible compromise.[J].1994,29.
- [9]Tormey DC,Gray R,Taylor SG 4th,etc.Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group.[J].1999,17(6).
- [10]Ewers Sven B\u00f6rje,Attewell Robyn,Baldetorp Bo,etc.Flow Cytometry Dna Analysis and Prediction of Loco-Regional Recurrences After Mastectomy in Breast Cancer[J].1992.
- [11]B, Fowble.Postmastectomy radiation: then and now.[J].1997,11.
- [12]G M, Freedman,B L, Fowble,A L, Hanlon,etc.A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger.[J].1998,41.
- [13]Overgaard, Marie,Jensen, Maj-Britt,Overgaard, Jens,etc.Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.[J].1999,353(9165).
- [14]Soete G,Van de-Steene-J,Storme G.Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link.[J].2000,55(3).
- [15]Recht A,Edge SB,Solin LJ,etc.Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology.[J].2001,19(5).
- [16]Halpin Murphy-P,Harris JR,Mendenhall NP,etc.Consensus Statement on postmastectomy radiation therapy.[J].1999,44(5).
- [17]Levine ML,Whelan TJ,Jadad AR,etc.Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis.[J].2000,18(6).
- [18]Overgaard, Marie,Hansen, Per S.,Overgaard, Jens,etc.Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy.[J].1997,337(14).
- [19]J, Ragaz,S M, Jackson,N, Le,etc.Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.[J].1997,337(14).